Patents by Inventor Chien-Yu FANG

Chien-Yu FANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10704051
    Abstract: The present invention provides an expression element and an expression cassette to establish a novel vector therefrom. The expression element of the present invention has an effect of enhancing the expression level of the target gene so that is highly industrial valuable. Accordingly, the present vector is taken as a novel tool for genetic engineering.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: July 7, 2020
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng Lin, Jyh-Perng Wang, Zeng-Weng Chen, Chien-Yu Fang, Hao-Zhen Zeng, Jian-Fong Lai, Weng-Zeng Huang, Shih-Ling Hsuan
  • Patent number: 10208093
    Abstract: The present invention provides a plasmid, method and kit for producing heat labile enterotoxin B-subunit based on a Bacillus subtilis expression system. By comparing with the conventional method in the art, the present invention has the advantages of high safety, good yield, and simplified process and is therefore favorable for the commercialization object of heat labile enterotoxin B-subunit in the application of vaccine adjuvant.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: February 19, 2019
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng Lin, Jyh-Perng Wang, Chien-Yu Fang, Zeng-Weng Chen, Ming-Wei Hsieh, Hao-Zhen Zeng, Jian-Fong Lai, Weng-Zeng Huang, Tzu-Ting Peng
  • Patent number: 10059749
    Abstract: The present invention provides proteins that are suitable to be used as the active ingredient in subunit vaccine against Mycoplasma spp. The present invention also provides a subunit vaccine made therefrom. Said proteins have been experimentally proved to have the capability of inducing sufficient immune response to avoid pigs from Mycoplasma spp. infection. Said vaccine may have one of said proteins as active ingredient; or may have two or more of said proteins and is formulated as a cocktail vaccine. The present vaccine not only is safer than the conventional vaccines but also has equal or even better immune efficiency than the conventional ones. Furthermore, fusion partners suitable for producing said proteins of high solubility are also proved, which can significantly reduce production cost.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: August 28, 2018
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng Lin, Jyh-Perng Wang, Zeng-Weng Chen, Chien-Yu Fang, Ming-Wei Hsieh, Ping-Cheng Yang
  • Publication number: 20180216119
    Abstract: The present invention provides an expression element and an expression cassette to establish a novel vector therefrom. The expression element of the present invention has an effect of enhancing the expression level of the target gene so that is highly industrial valuable. Accordingly, the present vector is taken as a novel tool for genetic engineering.
    Type: Application
    Filed: December 29, 2014
    Publication date: August 2, 2018
    Applicant: Agricultural Technology Research Institute
    Inventors: Jiunn-Horng LIN, Jyh-Perng WANG, Zeng-Weng CHEN, Chien-Yu FANG, Hao-Zhen ZENG, Jian-Fong LAI, Weng-Zeng HUANG, Shih-Ling HSUAN
  • Publication number: 20180208629
    Abstract: The present invention provides proteins that are suitable to be used as the active ingredient in subunit vaccine against Mycoplasma spp. The present invention also provides a subunit vaccine made therefrom. Said proteins have been experimentally proved to have the capability of inducing sufficient immune response to avoid pigs from Mycoplasma spp. infection. Said vaccine may have one of said proteins as active ingredient; or may have two or more of said proteins and is formulated as a cocktail vaccine. The present vaccine not only is safer than the conventional vaccines but also has equal or even better immune efficiency than the conventional ones. Furthermore, fusion partners suitable for producing said proteins of high solubility are also proved, which can significantly reduce production cost.
    Type: Application
    Filed: March 14, 2018
    Publication date: July 26, 2018
    Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: JIUNN-HORNG LIN, JYH-PERNG WANG, ZENG-WENG CHEN, CHIEN-YU FANG, MING-WEI HSIEH, PING-CHENG YANG
  • Patent number: 9951109
    Abstract: The present invention provides proteins that are suitable to be used as the active ingredient in subunit vaccine against Mycoplasma spp. The present invention also provides a subunit vaccine made therefrom. Said proteins have been experimentally proved to have the capability of inducing sufficient immune response to avoid pigs from Mycoplasma spp. infection. Said vaccine may have one of said proteins as active ingredient; or may have two or more of said proteins and is formulated as a cocktail vaccine. The present vaccine not only is safer than the conventional vaccines but also has equal or even better immune efficiency than the conventional ones. Furthermore, fusion partners suitable for producing said proteins of high solubility are also proved, which can significantly reduce production cost.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: April 24, 2018
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng Lin, Jyh-Perng Wang, Zeng-Weng Chen, Chien-Yu Fang, Ming-Wei Hsieh, Ping-Cheng Yang
  • Patent number: 9775893
    Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: October 3, 2017
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
  • Patent number: 9757441
    Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: September 12, 2017
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
  • Patent number: 9750790
    Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: September 5, 2017
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
  • Patent number: 9750791
    Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: September 5, 2017
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
  • Patent number: 9750792
    Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: September 5, 2017
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
  • Patent number: 9730990
    Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: August 15, 2017
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
  • Publication number: 20170202942
    Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.
    Type: Application
    Filed: March 8, 2017
    Publication date: July 20, 2017
    Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
  • Publication number: 20170196959
    Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.
    Type: Application
    Filed: March 8, 2017
    Publication date: July 13, 2017
    Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
  • Publication number: 20170182143
    Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.
    Type: Application
    Filed: March 8, 2017
    Publication date: June 29, 2017
    Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
  • Publication number: 20170182144
    Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.
    Type: Application
    Filed: March 8, 2017
    Publication date: June 29, 2017
    Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
  • Publication number: 20170182142
    Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better to immune effects.
    Type: Application
    Filed: March 8, 2017
    Publication date: June 29, 2017
    Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
  • Publication number: 20170151318
    Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.
    Type: Application
    Filed: December 19, 2016
    Publication date: June 1, 2017
    Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng LIN, Jyh-Perng WANG, Ming-Wei HSIEH, Zeng-Weng CHEN, Chien-Yu FANG, Hsueh-Tao LIU, Ping-Cheng YANG
  • Patent number: 9561267
    Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: February 7, 2017
    Assignee: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng Lin, Jyh-Perng Wang, Ming-Wei Hsieh, Zeng-Weng Chen, Chien-Yu Fang, Hsueh-Tao Liu, Ping-Cheng Yang
  • Publication number: 20170002045
    Abstract: The present invention provides a plasmid, method and kit for producing heat labile enterotoxin B-subunit based on a Bacillus subtilis expression system. By comparing with the conventional method in the art, the present invention has the advantages of high safety, good yield, and simplified process and is therefore favorable for the commercialization object of heat labile enterotoxin B-subunit in the application of vaccine adjuvant.
    Type: Application
    Filed: December 16, 2013
    Publication date: January 5, 2017
    Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jiunn-Horng Lin, Jyh-Perng Wang, Chien-Yu Fang, Zeng-Weng Chen, Ming-Wei Hsieh, Hao-Zhen Zeng, Jian-Fong Lai, Weng-Zeng Huang, Tzu-Ting Peng